Year None2023202220212020201920182017 Nov 21, 2023 Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference Nov 08, 2023 Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Oct 26, 2023 Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Oct 09, 2023 Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting Oct 05, 2023 Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Oct 02, 2023 Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration Sep 21, 2023 Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences Aug 31, 2023 Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference Aug 09, 2023 Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Aug 02, 2023 Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Nov 21, 2023 Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
Nov 08, 2023 Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Oct 26, 2023 Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Oct 09, 2023 Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
Oct 05, 2023 Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Oct 02, 2023 Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
Sep 21, 2023 Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
Aug 31, 2023 Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
Aug 09, 2023 Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 02, 2023 Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference
